{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Motzer RJ"],"funding":["NCI NIH HHS","Bristol Myers Squibb and ONO Pharmaceutical Company Limited"],"pagination":["e000891"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7359377"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(2)"],"pubmed_abstract":["Background
The extent to which response and survival benefits with immunotherapy-based regimens persist informs optimal first-line treatment options. We provide long-term follow-up in patients with advanced renal cell carcinoma (aRCC) receiving first-line nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) in the phase 3 CheckMate 214 trial. Survival, response, and safety outcomes with NIVO+IPI versus SUN were assessed after a minimum of 42 months of follow-up.Methods
Patients with aRCC were enrolled from October 16, 2014, through February 23, 2016. Patients stratified by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk and region were randomized to nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) every 3 weeks for four doses, followed by n"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial."],"pmcid":["PMC7359377"],"funding_grant_id":["P30 CA016672","P30 CA008748"],"pubmed_authors":["Kollmannsberger CK","Tykodi SS","Tannir NM","Amin A","Grunwald V","Gurney H","McDermott DF","Neiman V","McHenry MB","Saggi SS","Donskov F","Porta C","George S","Geertsen PF","Hammers HJ","Escudier B","Tomita Y","Aren Frontera O","Ravaud A","Choueiri TK","Powles T","Melichar B","Plimack ER","Barthelemy P","Salman P","Leibowitz-Amit R","Grimm MO","Motzer RJ","Rini BI"],"additional_accession":[]},"is_claimable":false,"name":"Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.","description":"Background
The extent to which response and survival benefits with immunotherapy-based regimens persist informs optimal first-line treatment options. We provide long-term follow-up in patients with advanced renal cell carcinoma (aRCC) receiving first-line nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) in the phase 3 CheckMate 214 trial. Survival, response, and safety outcomes with NIVO+IPI versus SUN were assessed after a minimum of 42 months of follow-up.Methods
Patients with aRCC were enrolled from October 16, 2014, through February 23, 2016. Patients stratified by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk and region were randomized to nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) every 3 weeks for four doses, followed by n","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jul","modification":"2026-07-16T09:39:09.073Z","creation":"2026-07-09T10:46:49.062Z"},"accession":"S-EPMC7359377","cross_references":{"pubmed":["32661118"],"doi":["10.1136/jitc-2020-000891"]}}